| Trial ID: | L3332 |
| Source ID: | NCT01521624
|
| Associated Drug: |
Metformin
|
| Title: |
Metformin Effects on Oxidative Stress Parameters in Newly Diagnosed Type 2 Diabetes Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Metformin
|
| Outcome Measures: |
Primary: Serum concentrations of various markers of oxidative stress, Serum concentrations of markers of oxidative stress (i.e. advanced glycation end products, advanced oxidation protein products, ferritin reducing ability of plasma) along with activities of antioxidant enzymes (i.e. paraoxonase1, lecithin cholesterol asyltransferase) are measured. To assess the change in inflammatory condition associated with fat tissue dysfunction (a close entity to oxidative stress) serum concentrations of fat tissue hormones (i.e. leptin, vaspin, adiponectin, visfatin)are also assessed., 12 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Tehran University of Medical Sciences
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
108
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2010-10
|
| Completion Date: |
2011-09
|
| Results First Posted: |
|
| Last Update Posted: |
2012-01-31
|
| Locations: |
Tehran University of Medical Sciences, Tehran, 13145-784, Iran, Islamic Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT01521624
|
